Modified Prescription-Event Monitoring Studies
Tóm tắt
Prescription-Event Monitoring (PEM) is a well established postmarketing surveillance technique designed to monitor the overall safety of newly marketed medicines as used in real-life clinical practice, usually in cohorts of at least 10000 patients. At the Drug Safety Research Unit in the UK we are now moving towards a more targeted safety surveillance known as Modified PEM (M-PEM). These studies combine the advantages of conventional PEM studies (in monitoring general safety and identification of unexpected risks of a medicine) with that of a more targeted safety study that addresses specific questions (to better understand known or partially known risks with a medicine). Through the use of enhanced data collection questionnaires, M-PEM expands the range of applications of conventional PEM, which include more detailed characterization of real-life drug use, adherence to prescribing recommendations and targeted analysis of events requiring special monitoring by regulatory authorities. A particularly useful application is the evaluation of the safety of a medicine in special populations or subgroups (e.g. patients switching from another therapy or patients with a particular risk factor) or following important changes in the product’s lifecycle (e.g. a licensing or formulation change). M-PEM studies therefore have an important contribution to make to pharmacovigilance and the risk management of medicines by providing valuable information on the use of new medications under real-life situations.
Tài liệu tham khảo
Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley & Sons Ltd, 2007: 307–16
Clark D, Harrison-Woolrych M. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions. Curr Drug Saf 2006; 1(2): 169–78
Kubota K. Prescription-event monitoring in Japan (J-PEM). Drug Saf 2002; 25(6): 441–4
Dodoo AN, Fogg C, Asiimwe A, et al. Pattern of drug utilization for treatment of uncomplicated malaria in urban Ghana following national treatment policy change to artemisinin-combination therapy. Malaria J 2009; 8: 2
Boshier A, Wilton LV, Shakir SAW. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU Int 2004; 93: 796–801
Hazell L, Cornelius V, Wilton L, et al. The safety profile of tadalafil as prescribed in general practice in England: results from a prescription-event monitoring study involving 16,129 patients. BJU International 2009; 103: 506–14
Pearce HM, Layton D, Wilton LV, et al. Deep vein thrombosis and pulmonary embolism reported in the prescription-event monitoring study of Yasmin®. Br J Clin Pharmacol 2005; 60(1): 98–102
Layton D, Marshall V, Boshier A, et al. Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. Drug Saf 2006; 29(8): 687–96
The National Information Governance Board. Register of approved section 251 applications [online]. Available from URL: http://www.nigb.nhs.uk/ecc/reg. [Accessed 2010 Sep 3]
Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158(9): 915–20
Leufkens HG, Urquhart J, Stricker BH, et al. Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems. J Epidemiol Community Health 1992 Aug; 46(4): 428–32
Layton D, Souverein PC, Heerdink ER, et al. Evaluation of risk profiles for gastrointestinal and cardiovascular adverse effects in non-selective NSAID and COX-2 inhibitor users: a cohort study using pharmacy dispensing data in The Netherlands. Drug Saf 2008; 31(2): 143–58
Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. J Clin Epidemiol 1994; 47: 731–7
Groves RM, Peytcheva E. The impact of nonresponse rates on nonresponse bias: a meta-analysis. Public Opin Q 2008; 72: 167–89
Cummings P, McKnight B, Greenland S. Matched cohort methods for injury research. Epidemiol Rev 2003; 25: 43–50
Whitaker HJ, Hocine M, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009; 18(1): 7–26
Strom B. Sample size considerations for pharmacoepidemiology studies. In: Strom B, editor. Pharmacoepidemiology. 4th ed. Chichester: John Wiley & Sons Ltd, 2005: 29–36
European Commission. Volume 9A. Pharmacovigilance for medicinal products for human use. September 2008 [online]. Available from URL: http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf [Accessed 2009 Apr 7]
Aurich-Barrera B, Wilton LV, Shakir SA. Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. Drug Saf 2009; 32(1): 43–54
Perrio M, Wilton LV, Shakir SAW. A modified prescription-event monitoring study to assess the introduction of flixotide Evohaler™ into general practice in England: an example of pharmacovigilance planning and risk monitoring. Pharmacoepidemiol Drug Saf 2007; 16: 969–78
Perrio M, Wilton LV, Shakir SAW. A modified prescription-event monitoring study to assess the introduction of seretide Evohaler™ in England: an example of studying risk monitoring in pharmacovigilance. Drug Saf 2007; 30(8): 681–95
Davies MN, Paiba N, Wilton LV, et al. A 12-month modified prescription-event monitoring report for travoprost [abstract no. P.020]. 7th Annual Conference of ISOP. 2007 Oct 21–24; Bournemouth. Drug Saf 2007; 30(10): 919–90
Davies MN, Wilton LV, Shakir SAW. Safety profile of modafinil used in general practice in England: a modified prescription-event monitoring study [abstract]. Drug Saf 2008; 31(10): 892
Buggy Y, Cornelius V, Wilton L, et al. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf 2011; 34(6): 501–9
Kasliwal R, Wilton LV, Shakir SA. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study. Drug Saf 2009; 32(6): 499–507
Food and Drug Administration. FDA issues public health advisory on Strattera (atomoxetine) for attention deficit disorder [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108493.htm [Accessed 2011 Apr 17]
European Medicines Agency. Procoralan® (ivabradine). European public assessment report. London: European Medicines Agency, 2005
Cephalon Europe. Effentora® buccal tablets: summary of product characteristics. Cephalon, 2008 [online]. Available from URL: http://www.medicines.org.uk/emc/medicine/21401 [Accessed 2011 Sep 8]
Astra Zeneca UK. Seroquel XL® tablets: summary of product characteristics. AstraZeneca, 2008 [online]. Available from URL: http://www.medicines.org.uk/emc/medicine/21175 [Accessed 2011 Sep 8]